Total Pageviews

Berkshire’s Energy Arm to Buy AltaLink, a Power Transmission Company

OMAHA â€" Berkshire Hathaway‘s energy division agreed on Thursday to buy AltaLink, Canda’s main energy transmission companies, for about $2.9 billion.

The deal â€" struck on the eve of Berkshire’s annual investor meeting here â€" is the latest takeover struck by the conglomerate’s energy arm, a sprawling group of businesses that encompasses $70 billion in assets and services 8.4 million customers.

Once known as MidAmerican Energy, the business has struck acquisitions like the $5.6 billion purchase of the Nevada utility NV Energy last year.

Now it is buying AltaLink, which operates power transmission services for about 85 percent of Alberta. Based in Calgary, it operates 280 substations and about 12,000 kilometers of transmission lines. The company reported about $487.3 million in revenue last year

Under the terms of the transaction, AltaLink will be run as a separate company within Berkshire Hathaway Energy.

“AltaLink’s values align with our core principles, including the commitment to employees and their safety, customers, regulators and relationships with key stakeholders,” Greg Abel, the chairman and chief executive of the Berkshire energy unit, said in a statement.

Berkshire Hathaway Energy is acquiring control of the company from SNC-Lavalin, the big Montreal-based engineering concern.

The deal is expected to close by early next year, pending regulatory approval.



U.S. Looks Into Wagers, Pro and Con, on Herbalife

Three federal agencies and one billionaire hedge fund manager have placed Herbalife under the microscope, scrutinizing whether the diet-supplements company is a pyramid scheme.

But Herbalife is not the only one under investigation. Some federal authorities are pursuing other inquiries that might expand the regulatory gaze from Herbalife to the traders who traffic in the company’s stock.

The authorities have trained their focus on traders with contrasting views of Herbalife, according to people briefed on the matter who spoke only on condition of anonymity. As one group wagered that Herbalife was a pyramid scheme â€" William A. Ackman, the billionaire hedge fund manager, has staked a $1 billion bet on that belief â€" other investors expected the company to emerge unscathed.

Neither side has been accused of wrongdoing. Still, a number of well-timed bets for and against Herbalife caught the eye of the Securities and Exchange Commission and the F.B.I., the people briefed on the matter said, raising questions about possible insider trading, disclosure violations and market manipulation.

The S.E.C. sent requests for documents to several investors betting on Herbalife’s success, the people said, including investment firms founded by Carl C. Icahn and George Soros. The S.E.C. and F.B.I. are also beginning to question whether Mr. Ackman’s hedge fund, Pershing Square Capital Management, improperly encouraged other traders to bet against Herbalife just before bad news emerged about the company, including Mr. Ackman’s initial announcement of his bet in December 2012.

For now, the inquiry has not yielded evidence of transgressions. And in a statement, Pershing Square said it did not “leak to anyone any information about its Herbalife position or its Dec. 20, 2012, presentation prior to its public release. In fact, the firm went to great lengths to avoid any premature disclosure.”

Yet some details of the presentation managed to slip out. The S.E.C. sent a subpoena to Pershing Square, the people said, as part of a previously unreported insider trading inquiry involving a winning bet against Herbalife. The inquiry appears to focus on a person outside Pershing Square who placed his own bet that Herbalife shares would falter â€" a trade he made after learning private details about Mr. Ackman’s campaign. Pershing Square is not the focus of that particular investigation.

Together, the investigations have thrust the authorities into the uncomfortable role of picking winners and losers in the billion-dollar game. If regulators conclude that Herbalife is a pyramid scheme, it could throw the company’s stock into a nose dive and produce a windfall for Mr. Ackman, who mobilized a network of interest groups against the company and personally met with federal authorities to outline his accusations. But if the S.E.C. files an action against those speculating in Herbalife’s shares, it could briefly distract from Mr. Ackman’s campaign.

As a central element of its campaign, Pershing Square lobbied the S.E.C. and the Federal Trade Commission to open civil inquiries into Herbalife. News of the F.T.C. investigation in March sent the company’s stock to its lowest level in eight months.

While the F.B.I. also opened a preliminary investigation into Herbalife, the inquiry has stalled, a person briefed on the matter said.

The S.E.C. and F.B.I., which might ultimately close the Herbalife-related investigations without taking action, declined to comment.

The focus of the S.E.C.’s insider trading investigation traces back to late 2012, when Mr. Ackman was preparing to announce his trade against Herbalife. Before the announcement, the people briefed on the matter said, one of Mr. Ackman’s junior employees mentioned the planned trade to his roommate.

The conversation was not necessarily illegal. The junior employee, who like Pershing Square has not been accused of any wrongdoing, may have shared information with his roommate in strict confidence.

But the roommate may have crossed a legal line when he helped a friend place a bet against Herbalife. After Mr. Ackman’s presentation pummeled the company’s stock, the people said, the friend reaped at least $20,000.

The investigation into the well-timed bet, a small fraction of a broader billion-dollar battle, is an unusual one for the S.E.C. The agency typically investigates leaks from corporate insiders about earnings and the sharing of other confidential tidbits.

Given the unusual circumstances and the small gains, it could be a tough case to file. Under the laws that govern insider trading, the bond between roommates does not inherently require a duty of confidentiality. But if the roommate violated an explicit promise to keep the information confidential, he could be liable. The junior employee has since left Pershing Square, one person said, a move that was unrelated to the investigation.

While Pershing Square is not suspected of wrongdoing in that matter, authorities are starting to scrutinize whether the hedge fund encouraged others traders to make well-timed bets against Herbalife.

Taking a page from Mr. Ackman’s playbook, Herbalife’s lawyers have provided the S.E.C. and other regulators with documents that show a surge in options trading soon before damaging news reports about Herbalife were published, a person briefed on the matter said. The trading also took place a month before Mr. Ackman announced his bet. The trades involved put options, contracts which allowed traders to place bearish bets on Herbalife without buying the company’s shares, and many of the options expired two days after Mr. Ackman’s presentation. The traders’ identity is unknown, and some options may have belonged to Pershing Square.

While the S.E.C. and F.B.I. are reviewing the information, they face a high hurdle to proving fraud or market manipulation, defined as “intentional conduct designed to deceive investors by controlling or artificially affecting” a stock. The S.E.C. has filed only a few such cases.

And even if Pershing Square spread advance word, it did not necessarily violate any rules. As long as Mr. Ackman told the truth â€" and did not violate Pershing Square’s own rules for disclosing information â€" he is free to exercise his First Amendment right to attack a company, as many hedge fund managers do.

Despite the barriers, Herbalife has continued to draw attention to Mr. Ackman’s campaign. A consulting group that works with Mr. Ackman’s team, Herbalife says, helped establish a website called StopHerbaLies while presenting the site as if it were the creation of community activists.

“If there is an undisclosed connection, financial or otherwise, between Ackman and that website, the S.E.C. should be interested,” said John DeSimone, chief financial officer of Herbalife.

Pershing Square has said that the outside consultant played a role but that the hedge fund was not involved. It is unclear whether the S.E.C. is investigating the issue.

Those supporting Herbalife, including the funds created by Mr. Soros and Mr. Icahn, have also drawn attention from the S.E.C.

It is possible the scrutiny stems from Mr. Ackman’s private plea to the S.E.C. last year to examine whether rival traders improperly collaborated to buy Herbalife shares and drive up the price of the stock. If Mr. Ackman’s rivals acted together to collectively buy 5 percent or more of Herbalife stock, they would have to disclose it within 10 days. Mr. Soros’s and Mr. Icahn’s investment funds have not been accused of wrongdoing.

Mr. Ackman, who says his effort to bring Herbalife to its knees stems from a sense of civic duty, has promised to donate any personal gain to charity. His investors, though, would still benefit from Herbalife’s troubles.

At the heart of Mr. Ackman’s wager are Herbalife’s marketing practices: The company distributes its products through a network of sales representatives, who Mr. Ackman contends are lured with the false promise of riches. He also argues that many representatives, who are forced to assume the risk of buying Herbalife’s diet shakes, are ultimately unable to sell to consumers.

Herbalife does not publicly disclose its sales results to consumers outside the network, but it does refer to a third-party survey showing that 87 percent of people who purchased Herbalife products were outside the network. The company, which commissioned that report, also cites a survey of former Herbalife members in the United States, 73 percent of whom reported joining Herbalife for the discounts, not to sell to consumers.

Still, if the bulk of Herbalife’s revenue is derived from recruiting, and not the sale of diet shakes to outside consumers, then the company could face regulatory action. The F.T.C. would typically have to show “unfair or deceptive” practices. The S.E.C., which has placed a renewed emphasis on pyramid schemes, would have to demonstrate that Herbalife misused money or misled investors about potential returns.

At least for now, the walls have not closed in on the 34-year-old company. Shares of Herbalife are more than $10 above where they were trading when Mr. Ackman revealed his position.



Bayer Nears Deal for Merck Consumer Unit

Merck, the big health care company, is close to a deal to sell its consumer unit to Bayer for about $14 billion, a person briefed on the matter said on Thursday.

A deal is expected to be announced in the coming days, before Merck holds an investor briefing in Boston on Tuesday.

Bayer is expected to pay cash and also swap some assets to complete the deal, which was a competitive process until recently. Reckitt Benckiser, the British health care giant, only recently backed out of the bidding. Sanofi, Procter & Gamble and Novartis were also previously interested in Merck’s consumer unit.

Divesting the unit, which includes popular products like the allergy medicine Claritin, Dr. Scholl’s shoe inserts and Coppertone sunscreen, will allow Merck to focus on its specialty pharmaceuticals division. Merck is refocusing as it grapples with patent expirations that pushed quarterly revenue down 4 percent in the first quarter, to $10.3 billion.

If Bayer contributes animal health assets, it would also allow Merck to build up its veterinary unit. In another move to reshape its portfolio, Merck last year offered to buy AZ Electronic Materials, a specialty chemical manufacturer, for 1.57 billion pounds, or about $2.57 billion.

Bayer, the German drug maker best known for its aspirin, also makes Alka-Seltzer and Aleve, the pain reliever. Acquiring Merck’s consumer unit would allow it to expand its focus on consumer products.

Shares in Merck, which has a market capitalization of $175 billion, were up 2 percent on Thursday.

The talks were reported earlier on Thursday by Bloomberg News and Reuters.

Merck’s chief executive, Kenneth Frazier, telegraphed the deal in a conference call announcing first-quarter earnings earlier this week.

“We are divesting assets and making structural changes to increase our operating leverage,” he said. “And we are also exploring strategic options for consumer and animal health.”

A transaction between Merck and Bayer would be the latest deal to reshape the health care landscape. Last week, the Swiss drug maker Novartis and its British rival GlaxoSmithKline agreed to swap $20 billion in assets. Also last week, Valeant and William A. Ackman made an unusual hostile bid for Allergan for about $50 billion. And in a third big deal last week, Zimmer agreed to buy Biomet for $13 billion.

Then on Monday, Pfizer expressed its interest in acquiring AstraZeneca, the British drug maker, in a $99 billion deal that would allow Pfizer to reincorporate in England.

Even before Pfizer announced its interest in a deal, the flurry of deals made this the fastest start to a year for health care deal-making ever.



Joining Rivals, Ares Management Set to Make Markets Debut

The biggest private equity firms were widely known to investors by the time they sold their shares to the public.

Now, a relatively unknown but rapidly growing firm is poised to join their ranks.

Ares Management, a private equity and debt investing firm based in Los Angeles, is expected to have its debut on the New York Stock Exchange on Friday, becoming the seventh major private equity firm to tap the public markets.

The initial public offering was priced conservatively on Thursday evening, raising $345.7 million for Ares and a large shareholder, the Abu Dhabi Investment Authority. The shares priced at $19 each, below an expected range of $21 to $23, according to a person briefed on the matter. At that level, the company is valued at about $4 billion.

The offering casts the spotlight on a private equity billionaire. Antony P. Ressler, 53, the chief executive and co-founder of Ares, who once worked in high-yield bonds at the now-defunct firm Drexel Burnham Lambert, has a stake worth about $1.2 billion based on the I.P.O. price.

Ares is following a path blazed in recent years by the likes of the Blackstone Group, Apollo Global Management, the Carlyle Group and Kohlberg Kravis Roberts.

Those firms â€" which spend much of their energy taking companies private to increase their value out of the scrutiny of stock investors â€" made for somewhat counter-intuitive debutantes on the public markets. But they have since used their publicly traded shares to help propel their growth.

For Ares, the stock offering is also an opportunity for branding. The firm was established in 1997 before spinning out from Apollo, a buyout and debt specialist to which Ares is often compared. The two firms have deep professional and personal ties: Mr. Ressler is a brother-in-law of Apollo’s chief executive, Leon D. Black.

But unlike Apollo, which regularly makes headlines for its multibillion-dollar deals, Ares tends to fly under the radar. In perhaps its most prominent deal recently, the firm teamed with a Canadian pension plan to buy the luxury retailer Neiman Marcus for $6 billion.

“They’re not a household name in the context of private equity,” said David Fann, the chief executive of TorreyCove Capital Partners, a firm that advises institutional investors in private equity. “They will be now.”

Ares’s market debut comes several years after a string of I.P.O.s by the giants of private equity. Blackstone, in a deal that aroused scrutiny from Congress and helped start a debate over the tax treatment of private equity, sold its shares to the public in 2007, creating a windfall for its founders, Stephen A. Schwarzman and Peter G. Peterson. K.K.R. got a New York listing in 2010, and Apollo and Carlyle followed.

Ares is similarly classifying itself as a publicly traded partnership, greatly reducing its tax bill. While Congress is not expected to change this tax treatment soon, the issue continues to raise eyebrows in Washington and was a focus of recently proposed legislation by Representative Dave Camp, a Michigan Republican.

Beyond politics, publicly traded private equity firms face a number of challenges. Their earnings tend to be uneven â€" dependent in large part on the firms’ ability to sell their investments â€" and can be difficult for Wall Street analysts to value. Mr. Schwarzman recently complained on a conference call with analysts that Blackstone was trading at a lower multiple than BlackRock, a giant asset management firm that lacks a private equity arm.

The market for initial public offerings, too, has been choppy. An exchange-traded fund created by Renaissance Capital that tracks the performance of recent I.P.O.s is down almost 2 percent so far this year. The Standard & Poor’s 500-stock index has climbed 2 percent during that time.

Big private equity firms have reaped large profits from selling their investments into buoyant markets, fueling a rise in their shares. Against a 30 percent increase in the S.&P. 500 last year, shares of Blackstone doubled, while Apollo’s stock rose more than 80 percent. This year, however, their shares have slumped.

Ares is smaller than these firms, with about $74 billion in assets under management. It is closer in size to Oaktree Capital Management, a publicly traded firm with about $86 billion in assets under management, and to the Fortress Investment Group, with $62.5 billion in assets under management.

Ares, which includes businesses in real estate and direct lending, said its economic net income â€" a measure that includes unrealized investment gains â€" was $198 million last year, 29 percent lower than the previous year. But its distributable earnings, which show the cash it generated, rose 40 percent to $228.6 million.

Going public will help Ares reduce its debt, the firm said in its prospectus. It could also help the firm make acquisitions and attract new talent by offering stock-based compensation. The offering is being led by JPMorgan Chase and Bank of America Merrill Lynch.

“You’re seeing a period of very strong availability in debt, coupled with a very strong, at least for now, capital markets moment,” said Breck N. Hancock, a partner at the law firm Goodwin Procter. “That certainly explains why this would be a good moment in time for their own I.P.O.”

To an unusual degree, Ares has also focused on lending directly to companies. This segment has grown to encompass $27 billion of the firm’s assets under management, dwarfing the $10 billion private equity business.

Firms like Ares, known as non-bank lenders, have been active especially in Europe, as banks have pulled out of certain markets. And they have also drawn controversy, gaining the nickname “shadow banks.”

“I’ve never really thought that we were in the shadows,” Michael J Arougheti, a co-founder and the president of Ares, said in a recent interview on CNBC. “Non-bank lenders have effectively become the banks of today.”



Pfizer Looks for a Quick Strike on AstraZeneca

Time often benefits bidders rather than targets - that’s why Kraft left its British rival Cadbury flailing for months after making a takeover approach. But the dynamics of Pfizer’s interest in AstraZeneca are unusual. Pfizer has good reason to seek a quick negotiated deal.

The bid battle for Cadbury in 2009 led to a reform of British takeover rules. As a result, after its declaration of interest in AstraZeneca on April 28, Pfizer has to make a formal offer within 28 days â€" or withdraw for six months unless AstraZeneca agrees otherwise. The two sides are in stalemate. Pfizer is courting AstraZeneca’s shareholders and the British government at the same time. AstraZeneca is waiting for a better offer than the current 46.61 pounds a share. It is seeking to persuade shareholders â€" who would retain a stake in the enlarged company â€" that a deal would be risky.

Pfizer has one good reason to go hostile if Astra does not budge. Walking away would expose it to the risk that the United States government changes its fiscal regime. Then Pfizer could no longer take advantage of the possibility to “invert” its tax domicile into Britain through the takeover.

Hostile deals are not unprecedented in the pharmaceutical industry. But they have costs. Typically, they require a 10 percent bump in price compared with 5 percent to 7 percent in negotiated deals, according to one top banker. Moreover, the bidder cannot review the target’s books and thus assess its true worth.

Britain’s Takeover Panel sets a 60-day limit for the acceptance of offers and allows an additional 21 days for the deal’s various conditions to be met. It grants an extension only if the target company wants one. If a hostile Pfizer did not secure all regulatory approvals in 81 days, the bid would lapse. Alternatively, waiting for approval first would give AstraZeneca more time to build its defense. With possible Chinese clearance needed, the process could drag. Pfizer will therefore want a friendly deal completed as quickly as possible.

AstraZeneca’s chief executive, Pascal Soriot, should not take too much comfort. His shareholders are expecting a deal. The company’s share price can be seen as pricing in a 75 percent chance of a deal happening at 52 pounds a share, adjusting for the time value of money. Investors seem to want Mr. Soriot to use his tactical advantage to extract a good price rather than preserve a standalone AstraZeneca stuck at its pre-deal value.

Christopher Hughes is Europe, Middle East and Africa editor and Neil Unmack is a columnist for Reuters Breakingviews. For more independent commentary and analysis, visit breakingviews.com.



K.K.R. Seeks to Attract Investments as Small as $10,000

Only the wealthiest and most sophisticated investors are allowed to put money into the high-stakes buyouts done by Kohlberg Kravis Roberts. But that may be changing.

K.K.R. is working with another firm to allow investors to commit a minimum of just $10,000 for exposure to its private equity funds, according to a filing with regulators on Thursday. The new investment product, subject to approval by the Securities and Exchange Commission, would be the first time K.K.R. has taken smaller investors into its core business of buyouts.

Private equity giants, which typically raise their funds from institutions and ultrawealthy individuals, are trying to gain access to so-called retail investors, who are seen as a vast new source of capital. A rival of K.K.R., the Carlyle Group, introduced a product last year that, in partnership with a third-party firm, allowed investors to commit as little as $50,000 to invest in Carlyle’s private equity funds.

Like Carlyle, K.K.R. has structured its product in a way that may help it navigate regulatory challenges.

A legal obstacle stems from the Investment Company Act of 1940, which has had the effect of limiting individual private equity investors to those who have at least $5 million in investments. Both Carlyle and K.K.R., however, are trying to appeal to “accredited” investors, whose net worth exceeds $1 million, not including their primary home â€" a low bar for the industry.

To get around the legal hurdles, they are relying on third-party firms to manage the investments. K.K.R. is working with an investment firm called Altegris Advisors, which aims to register a fund under the 1940 law.

The fund, which charges a 1.2 percent annual management fee, plans to invest at least 70 percent of its assets in private equity funds sponsored by K.K.R. Pending regulatory approval, it will offer shares at $10 each until it has raised $25 million for its initial closing. After that, shares will be available for purchase monthly.

Investors’ ability to sell their shares will be limited at first. After two years, the fund may hold tender offers for shares, according to the filing. After the third year, the fund plans to recommend repurchases on a quarterly basis. At that point, any investors who have held their shares for less than a year and want to sell will have to pay a 2 percent fee.

In addition, the fund may make shares available for secondary sales through a platform operated by Nasdaq Private Market, a marketplace for buying and selling shares of private companies, the filing said.

The S.E.C. did not immediately respond to a request for comment.

To some private equity experts, the industry’s effort to gather smaller checks seems worrisome. Josh Lerner, a professor at Harvard Business School, said that private equity firms had in the past shown greater discipline in staying away from retail investors.

“If we’re going to end up with an industry that is dominated by hot money flowing into the sectors that are the most overheated flavors of the moment,” Mr. Lerner said, “it probably doesn’t augur well for the kinds of returns private equity is going to deliver.”



Britain Bars Former UBS Senior Trader From Financial Industry

LONDON - Britain’s Financial Conduct Authority on Thursday barred John Christopher Hughes, a former senior trader at UBS, from working in the financial industry, but did not fine him for failing to report a slush fund of money used to help manage his desk’s daily profit and losses.

The fund was part of a fraudulent scheme resulting in $2.3 billion in trading losses incurred by Kweku M. Adoboli, who was junior to Mr. Hughes. Mr. Adoboli was sentenced to seven years in prison in November 2012 after being found guilty of two counts of fraud.

In 2011, Mr. Hughes was the most senior trader on the global synthetic equities desk in UBS’s London office. According to the Financial Conduct Authority, part of Mr. Adoboli’s trading scheme involved creating and using an undeclared fund of profits, called the “umbrella,” to manipulate the desk’s reported profits and losses.

Mr. Hughes knew about the fund. He told regulators that although he “felt a bit sick” upon learning about it in January, he quickly got comfortable with the idea and, by February, he and Mr. Adoboli chatted online about when to take money out and when to bulk up the fund. He said that he knew he was “lying every day.”

Mr. Hughes knew that UBS would not authorize the “umbrella,” and in barring him, the Financial Conduct Authority said Mr. Hughes was “not a fit and proper person.”

“Approved people should operate to the highest standards of integrity,” said Tracey McDermott, the regulator’s director of enforcement and financial crime. “This means not only doing the right thing themselves but also challenging, and blowing the whistle on, those who are not. Hughes failed to do so with catastrophic consequences.”

UBS was fined 29.7 million pounds, or about $50 million, in November 2012 for failing to detect or prevent the unauthorized trading. Though Mr. Hughes was aware that the “umbrella” fund was being used to manipulate the desk’s results, he said he was not aware of the rouge trades.

The regulator’s office said Mr. Hughes had represented himself in the case.

Mr. Hughes was suspended soon after Mr. Adoboli was arrested in September 2011. After a disciplinary hearing at the bank, he was fired in January 2012 and did not contest the decision, the regulator said.

The regulator said that it considered the ban the “appropriate” course of action.

UBS employees fired for gross misconduct lose all of their deferred compensation.

In November 2012, Financial News reported that Mr. Hughes was setting up an online gambling venture called BetsofMates.com. Mr. Hughes could not be reached for comment.

This post has been revised to reflect the following correction:

Correction: May 1, 2014

An earlier version of this article misstated the name of the UBS trader. He is John Christopher Hughes, not Christopher Hughes.



Britain Bars Former UBS Senior Trader From Financial Industry

LONDON - Britain’s Financial Conduct Authority on Thursday barred John Christopher Hughes, a former senior trader at UBS, from working in the financial industry, but did not fine him for failing to report a slush fund of money used to help manage his desk’s daily profit and losses.

The fund was part of a fraudulent scheme resulting in $2.3 billion in trading losses incurred by Kweku M. Adoboli, who was junior to Mr. Hughes. Mr. Adoboli was sentenced to seven years in prison in November 2012 after being found guilty of two counts of fraud.

In 2011, Mr. Hughes was the most senior trader on the global synthetic equities desk in UBS’s London office. According to the Financial Conduct Authority, part of Mr. Adoboli’s trading scheme involved creating and using an undeclared fund of profits, called the “umbrella,” to manipulate the desk’s reported profits and losses.

Mr. Hughes knew about the fund. He told regulators that although he “felt a bit sick” upon learning about it in January, he quickly got comfortable with the idea and, by February, he and Mr. Adoboli chatted online about when to take money out and when to bulk up the fund. He said that he knew he was “lying every day.”

Mr. Hughes knew that UBS would not authorize the “umbrella,” and in barring him, the Financial Conduct Authority said Mr. Hughes was “not a fit and proper person.”

“Approved people should operate to the highest standards of integrity,” said Tracey McDermott, the regulator’s director of enforcement and financial crime. “This means not only doing the right thing themselves but also challenging, and blowing the whistle on, those who are not. Hughes failed to do so with catastrophic consequences.”

UBS was fined 29.7 million pounds, or about $50 million, in November 2012 for failing to detect or prevent the unauthorized trading. Though Mr. Hughes was aware that the “umbrella” fund was being used to manipulate the desk’s results, he said he was not aware of the rouge trades.

The regulator’s office said Mr. Hughes had represented himself in the case.

Mr. Hughes was suspended soon after Mr. Adoboli was arrested in September 2011. After a disciplinary hearing at the bank, he was fired in January 2012 and did not contest the decision, the regulator said.

The regulator said that it considered the ban the “appropriate” course of action.

UBS employees fired for gross misconduct lose all of their deferred compensation.

In November 2012, Financial News reported that Mr. Hughes was setting up an online gambling venture called BetsofMates.com. Mr. Hughes could not be reached for comment.

This post has been revised to reflect the following correction:

Correction: May 1, 2014

An earlier version of this article misstated the name of the UBS trader. He is John Christopher Hughes, not Christopher Hughes.



Lazard’s Earnings More Than Double on Jump in M.&A. Activity

The strong burst of deal-making this year has been good to Lazard.

The investment bank reported $81 million in first-quarter net income on Thursday, more than doubling what it earned in the period a year earlier as Lazard claimed significant merger advisory assignments.

That profit translates to 61 cents a share. On average, analysts expected the firm to earn 54 cents a share, according to Standard & Poor’s Capital IQ.

The latest results stem from one of the most robust starts to a year for deal-making. Over $1.1 trillion in mergers had been announced by April 25, according to Thomson Reuters.

Much of that resurgence has come from confidence among corporate boards and management teams that now is the time to buy companies, according to Kenneth M. Jacobs, Lazard’s chairman and chief executive. Favorable financing has been available for years, and companies’ valuations, while rising over the past year, still remain attractive for would-be buyers.

Now, corporate acquirers feel better about moving ahead on a deal, he said. And so long as the overall environment continues at this pace, deals should continue.

“We feel cautiously optimistic,” Mr. Jacobs said by phone.

So-called independent and boutique investments banks - Lazard is the largest of them - are seen as important bellwethers of the deal industry. Unlike more diversified firms like Goldman Sachs and JPMorgan Chase, their primary business is advising on transactions, without the distractions of other operations like trading desks.

Lazard has had its hand in a number of the big transactions this year. Among them were GlaxoSmithKline’s complicated asset swaps with Novartis, a series of transactions potentially worth more than $23 billion; TIAA-CREF’s $6.25 billion acquisition of Nuveen Investments; and the utility company Pepco’s $6.8 billion sale to Exelon.

Deals that closed during the quarter - an important distinction, since investment banks receive the bulk of their fees when a transaction is completed - included Health Management Associates’ $7.6 billion sale to Community Health Systems and AT&T’s $4.1 billion deal for Leap Wireless.

Over all, Lazard’s mainstay advisory business reported $275.5 million in revenue, up 64 percent from the period a year earlier.

Its asset management arm, which now oversees $189 billion in assets, disclosed a 9 percent gain in revenue, to $262.3 million. Mr. Jacobs said that while the business has bet in large part on the booming stock markets, it has rolled out financial products that cover an array of investment areas.

The firm also held the line on expenses. Its ratio of compensation payouts to revenue reached 58.8 percent in the quarter, about a percentage point lower than in the year-earlier period. Noncompensation expenses as a percentage of revenue fell to 19.1 percent from 24.1 percent.

Lazard’s first-quarter results compare favorably with those of its publicly traded competitors. Evercore Partners reported last week that adjusted profit from continuing operations fell 12 percent from the year-earlier period, while net income tumbled 98 percent at Greenhill & Company.

Shares in Lazard have risen 3.8 percent this year, closing on Wednesday at $47.05. By comparison, Evercore’s stock has fallen 10.6 percent and Greenhill’s about 13 percent.

Shares in the newest publicly traded independent investment bank, Moelis & Company, have risen about 6.2 percent since its market debut last month. Over that period, Lazard’s stock has climbed about 4.6 percent.

Mr. Jacobs ascribed his firm’s performance to its high level of senior deal makers with connections to corporate decision makers around the globe.

“There are very few firms around the world that can match that,” he said. “It’s what differentiates us from some of our newer competitors.”



Lazard’s Earnings More Than Double on Jump in M.&A. Activity

The strong burst of deal-making this year has been good to Lazard.

The investment bank reported $81 million in first-quarter net income on Thursday, more than doubling what it earned in the period a year earlier as Lazard claimed significant merger advisory assignments.

That profit translates to 61 cents a share. On average, analysts expected the firm to earn 54 cents a share, according to Standard & Poor’s Capital IQ.

The latest results stem from one of the most robust starts to a year for deal-making. Over $1.1 trillion in mergers had been announced by April 25, according to Thomson Reuters.

Much of that resurgence has come from confidence among corporate boards and management teams that now is the time to buy companies, according to Kenneth M. Jacobs, Lazard’s chairman and chief executive. Favorable financing has been available for years, and companies’ valuations, while rising over the past year, still remain attractive for would-be buyers.

Now, corporate acquirers feel better about moving ahead on a deal, he said. And so long as the overall environment continues at this pace, deals should continue.

“We feel cautiously optimistic,” Mr. Jacobs said by phone.

So-called independent and boutique investments banks - Lazard is the largest of them - are seen as important bellwethers of the deal industry. Unlike more diversified firms like Goldman Sachs and JPMorgan Chase, their primary business is advising on transactions, without the distractions of other operations like trading desks.

Lazard has had its hand in a number of the big transactions this year. Among them were GlaxoSmithKline’s complicated asset swaps with Novartis, a series of transactions potentially worth more than $23 billion; TIAA-CREF’s $6.25 billion acquisition of Nuveen Investments; and the utility company Pepco’s $6.8 billion sale to Exelon.

Deals that closed during the quarter - an important distinction, since investment banks receive the bulk of their fees when a transaction is completed - included Health Management Associates’ $7.6 billion sale to Community Health Systems and AT&T’s $4.1 billion deal for Leap Wireless.

Over all, Lazard’s mainstay advisory business reported $275.5 million in revenue, up 64 percent from the period a year earlier.

Its asset management arm, which now oversees $189 billion in assets, disclosed a 9 percent gain in revenue, to $262.3 million. Mr. Jacobs said that while the business has bet in large part on the booming stock markets, it has rolled out financial products that cover an array of investment areas.

The firm also held the line on expenses. Its ratio of compensation payouts to revenue reached 58.8 percent in the quarter, about a percentage point lower than in the year-earlier period. Noncompensation expenses as a percentage of revenue fell to 19.1 percent from 24.1 percent.

Lazard’s first-quarter results compare favorably with those of its publicly traded competitors. Evercore Partners reported last week that adjusted profit from continuing operations fell 12 percent from the year-earlier period, while net income tumbled 98 percent at Greenhill & Company.

Shares in Lazard have risen 3.8 percent this year, closing on Wednesday at $47.05. By comparison, Evercore’s stock has fallen 10.6 percent and Greenhill’s about 13 percent.

Shares in the newest publicly traded independent investment bank, Moelis & Company, have risen about 6.2 percent since its market debut last month. Over that period, Lazard’s stock has climbed about 4.6 percent.

Mr. Jacobs ascribed his firm’s performance to its high level of senior deal makers with connections to corporate decision makers around the globe.

“There are very few firms around the world that can match that,” he said. “It’s what differentiates us from some of our newer competitors.”



A Dinner Among Survivors of the Financial Crisis

Call it the financial crisis survivors’ club.

Lloyd C. Blankfein, the chief executive of Goldman Sachs, went to dinner recently with Jamie Dimon, the chief executive of JPMorgan Chase, and Peter Sands, the chief executive of the British bank Standard Chartered, according to Mr. Blankfein. The three men and their wives traded stories from the dark days of 2008, when it seemed as if the financial world was crumbling around them.

More than five years later, the three executives are still at the helms of their banks. Many of their colleagues - including John J. Mack of Morgan Stanley, Vikram S. Pandit of Citigroup, Kenneth D. Lewis of Bank of America and Robert E. Diamond Jr. of Barclays - did not have the same longevity.

On Wednesday evening, Mr. Blankfein recalled the dinner while chatting with a handful of JPMorgan employees at a charity event held on the floor of the New York Stock Exchange. Several reporters were standing close by.

The Goldman chief had just finished giving a speech praising Team Rubicon, a group that organizes military veterans to volunteer in disaster relief work. Mr. Blankfein and his wife, Laura, were the biggest individual contributors to the event, which included an auction to raise money for the veterans group.

Goldman, for its part, runs an effort called the Veterans Integration Program, which helps veterans make the transition to possible jobs at the Wall Street bank.

Mr. Blankfein was all smiles on Wednesday. He pointed out the difference in height between himself and the towering Jacob Wood, the chief executive of Team Rubicon, saying he felt like a “different species.” Drink in hand, he worked the room, cracking jokes and, when he ran into the JPMorgan employees, telling the anecdote about the dinner.

“If you look in the books - if you go check,” Mr. Blankfein said, “who are still in their C.E.O. jobs from before the crisis?”



Awaiting Alibaba’s I.P.O.

The Alibaba Group, the Chinese Internet giant that is about to go public in the United States, is said to be in talks with its Alipay payment affiliate about regaining a stake in the business, Michael J. de la Merced writes in DealBook. The two sides have been in talks for nearly a year and a half, and no agreement is imminent. In any case, the possibility that Alibaba could be formally reunited with its payment division would be of great interest to the company’s future shareholders.

Alibaba’s I.P.O. is expected to be the largest technology stock offering in history, but few in Silicon Valley seem to care, Farhad Manjoo writes in the State of the Art column. “San Francisco’s artisanal toast bars have not been abuzz with commentary on Jack Ma, Alibaba’s chairman, and Palo Alto’s Tesla dealerships aren’t bracing for a surge in new buyers,” he writes.

But while Alibaba’s stock offering has barely registered among the Silicon Valley elite, it may start a global fight for users. For quite a while, American and Chinese technology companies have looked to global domination, each essentially ignoring the other. Now, Alibaba’s I.P.O. could signal a shift, “the end of an era of mutually beneficial provincialism,” Mr. Manjoo writes.

LONE BANKER  |  The economic catastrophe of 2008 was the largest of its kind since the Depression, but to date, only one investment banker, Kareem Serageldin, has gone to jail for the financial crisis, Jesse Eisinger writes in The New York Times Magazine. “Many assume that the federal authorities simply lacked the guts to go after powerful Wall Street bankers, but that obscures a far more complicated dynamic,” Mr. Eisinger writes.

“During the past decade, the Justice Department suffered a series of corporate prosecutorial fiascos, which led to critical changes in how it approached white-collar crime. The department began to focus on reaching settlements rather than seeking prison sentences, which over time unintentionally deprived its ranks of the experience needed to win trials against the most formidable law firms,” he adds. Part of the Justice Department’s futility can be traced to the rise of its prosecutors’ ambitions, Mr. Eisinger writes. There was also fear that Wall Street institutions were simply too big to indict.

Some federal prosecutors say that the cases that might have landed top Wall Street executives in jail were too complex to investigate and would have been too difficult to explain to juries. They also suggest that deferred prosecutions, with their billions in settlements and additional oversight actions, can be stricter punishments than indictments. But, Mr. Eisinger writes, the fact remains that few, if any, corporate executives ever go to prison anymore. And perhaps, he adds, “One reason Americans have come to begrudge the wealthy is a resentment of their culture of impunity.”

REGULATOR SAYS BANKS ERRED ON TROUBLED MORTGAGES  |  A federal regulator confirmed on Wednesday that the country’s biggest banks committed widespread errors in dealing with homeowners who faced foreclosures at the height of the mortgage crisis, Michael Corkery writes in DealBook. But the report, released by the Office of the Comptroller of the Currency, is unlikely to put to rest questions from lawmakers and others about the extent of the problems.

The latest analysis found that at least 9 percent of the errors discovered in the review involved banks improperly denying loan modifications that would have prevented foreclosures. The report also found that more than half of the errors related to administrative flaws and improper fees charged to homeowners during the foreclosures process. But, Mr. Corkery writes, “While the new report from the comptroller’s office offers a snapshot of the extensive foreclosure problems during the crisis, it does not provide a complete picture of the morass that millions of homeowners encountered in 2009 and 2010.”

Faced with criticism that the reviews were taking too long and costing hundreds of millions in consulting fees, banks and regulators reached settlements and stopped the process after only a small fraction of the mortgage files had been reviewed. But the report, released on Wednesday, shows that banks had made even less progress in reviews than previously disclosed.

ON THE AGENDA  |  The Challenger job cut report is out at 7:30 a.m. Weekly jobless claims are released at 8:30 a.m. Personal income and spending reports are out at 8:30 a.m. The Purchasing Managers’ Manufacturing Index is out at 9:45 a.m. The ISM manufacturing composite index is released at 10 a.m. Construction spending data is also out at 10 a.m. Happy May Day.

On the Hill: Janet L. Yellen, chairwoman of the Federal Reserve, speaks to the Independent Community Bankers of America in Washington at 8:30 a.m. The House Subcommittee on Capital Markets and Government Sponsored Enterprises holds a hearing at 9:30 a.m. entitled “Legislative Proposals to Enhance Capital Formation for Small and Emerging Growth Companies, Part II.”

FACEBOOK CHANGES RULES FOR LOG-INS  |  Facebook announced on Wednesday that its 1.3 billion users would be able to reveal a little less about themselves, Vindu Goel writes in The New York Times. Before, depending on the site or app, using the Facebook log-in exposed much of users’ Facebook information to that app or site. But now, users will be able to limit what they reveal to the site or app to just their email addresses and public profile information. Facebook also announced that it was testing another feature to allow people to use their Facebook identity to gain access to other sites or apps through a button marked “Log in anonymously.” With the moves, Facebook is responding to longtime user complaints.

 

Mergers & Acquisitions »

Hoping for Stability, Utility Operator Exelon Agrees to Buy Pepco for $6.8 BillionHoping for Stability, Utility Operator Exelon Agrees to Buy Pepco  |  The $6.8 Billion acquisition is the latest effort by a utility to cut costs by growing larger as the industry contends with declining electricity sales and natural gas prices. DealBook »

High Price in Utility Deal  |  There is a strategic logic to a merger between Exelon and Pepco, Christopher Swann of Reuters Breakingviews writes, yet there is also a high premium. DealBook »

AT&T May Be Interested in DirecTV  |  AT&T is said to have approached DirecTV, a satellite television company, about a possible acquisition, The Wall Street Journal writes, citing unidentified people familiar with the situation. WALL STREET JOURNAL

Merck Considering Sale of Drug Portfolio  |  Merck is said to be exploring a possible sale of a portfolio of mature drugs that could fetch more than $15 billion, Reuters writes, citing unidentified people familiar with the situation. REUTERS

INVESTMENT BANKING »

Profit Falls at Lloyds Bank, but Outlook Improves  |  The Lloyds Banking Group said first-quarter profit declined 24.7 percent, to about $2 billion, from the period a year earlier. The bank is still aiming to restart paying a dividend this year. DealBook »

Britain Bars Former UBS Senior Trader From Financial Industry  |  The Financial Conduct Authority of Britain barred the former senior UBS trader, John Christopher Hughes, from the financial industry for his role in a $2.3 billion trading loss incurred by another former trader, Kweku M. Adoboli, who is serving a seven-year prison sentence for fraud. DealBook »

What Bank of America’s Accounting Mistake Can Teach the MarketWhat Bank of America’s Accounting Mistake Can Teach the Market  |  Do big banks have strong enough management of their risks and good internal controls to detect accounting problems? Mayra Rodríguez Valladares examines the problem in the Another View column.
DealBook »

PRIVATE EQUITY »

Profit at Carlyle Falls 18% as Real Estate Investments UnderperformProfit at Carlyle Falls 18% as Real Estate Investments Underperform  |  Private equity may be a booming business, but the Carlyle Group was weighed down by declines in its global market strategies business and real assets segment. DealBook »

Pioneer of Leveraged Buyouts Brings Wit to Charity GalaPioneer of Leveraged Buyouts Brings Wit to Charity Gala  |  Thomas H. Lee, who was honored on Tuesday night for his philanthropy at an event organized by the UJA-Federation of New York, knows how to work a room. DealBook »

Silver Lake Unit Is Said to Have Spun Off to Raise New Fund  |  The middle-market unit of the private equity firm Silver Lake Management is said to have spun off as a separate company after its parent gave up on efforts to raise a $1 billion fund, Bloomberg News reports, citing unidentified people familiar with the situation. The new firm is now aiming to raise $600 million to make private equity investments in technology companies focused on growth. BLOOMBERG NEWS

HEDGE FUNDS »

Abercrombie Settles Board Fight With Engaged CapitalAbercrombie Settles Board Fight With Engaged Capital  |  The move will end a battle between Abercrombie & Fitch and Engaged Capital, which argued that the retailer needed new blood on its board to help turn around a slump that has lasted for years. DealBook »

Funds for Troubled Mortgages Are on the RiseFunds for Troubled Mortgages Are on the Rise  |  Distressed-mortgage funds are suddenly hot, but it is unclear whether the strategy of investing in delinquent home loans will live up to the marketing hype. DealBook »

I.P.O./OFFERINGS »

Energizer to Split in TwoEnergizer to Split in Two  |  Energizer said that it planned to split into two publicly traded companies: one for household products like Energizer batteries, the other for personal care products like Schick razors. DealBook »

Energizer Split Leaves Biggest Problem IntactEnergizer Split Leaves Biggest Problem Intact  |  The main challenge is mustering enough resources to take on the consumer products behemoth Procter & Gamble, Kevin Allison writes for Reuters Breakingviews. DealBook »

Time Warner’s Profit Rises as Spinoff Nears  |  The growth from movie and cable businesses helped spur a 9 percent increase in Time Warner’s revenue, to $7.5 billion from $6.9 billion in the period a year earlier, The New York Times writes. The company said it was on track to spin off its Time Inc. magazine business by the end of June. NEW YORK TIMES

Box May Delay I.P.O.  |  Box, an online storage start-up, is said to be pushing back plans for an initial public offering until June or later because of weakening demand for technology stocks, The Wall Street Journal reports. WALL STREET JOURNAL

VENTURE CAPITAL »

Silicon Valley Sometimes Needs More Bureaucracy  |  A female engineer’s complaint of a culture of bullying at GitHub demonstrates the value of a human resources department, Claire Cain Miller writes in The Upshot. NEW YORK TIMES UPSHOT

A Club at M.I.T. Is Giving Out Bitcoin to Students  |  The M.I.T. Bitcoin Club plans to give every undergraduate student on campus $100 worth of Bitcoin in the fall to see what would happen when an entire community has access to a digital currency, The Verge writes. THE VERGE

Silicon Valley Has a Stake in India’s Elections  |  Indian immigrants who have worked in Silicon Valley are using their experiences in United States politics to try to bring change to India’s government, Quartz reports. QUARTZ

LEGAL/REGULATORY »

Intrade Co-Founder Opens Fantasy Sports SiteIntrade Co-Founder Opens Fantasy Sports Site  |  By styling the new company as a fantasy sports site and not a betting and prediction market, Tradesports.com hopes to avoid the kind of regulatory trouble that hastened Intrade’s demise. DealBook »

Senators Express Concern on Reverse Mortgage RulesSenators Express Concern on Reverse Mortgage Rules  |  Senators Charles Schumer and Barbara Boxer urged the Department of Housing and Urban Development to clarify loans that have saddled middle-age children with their parents’ mortgages. DealBook »

Forecasting a Speedup in Growth, Fed Again Cuts Bond Purchases  |  At its policy-making meeting, the Federal Reserve said it would pare its purchases of Treasury and mortgage-backed securities by $10 billion, to $45 billion a month, beginning this month, The New York Times reports. NEW YORK TIMES

Once More, Economy Exhibits Weakness  |  The economy grew only 0.1 percent in the first quarter, hurt by harsh winter weather and slow gains in inventories after stockpiles grew robustly in the second half of 2013, The New York Times reports. NEW YORK TIMES

Clinton Defends His Economic Legacy  |  Amid charges of being out of step with income inequality, former President Bill Clinton spoke out about the effect of policies like the welfare overhaul and the earned-income tax credit â€" a message his wife could use if she runs in 2016, The New York Times writes. NEW YORK TIMES



Lloyds Profit Falls, But Outlook Improves

LONDON - Lloyds Banking Group said on Thursday that its profit declined 24.7 in the first quarter, but that its outlook continued to improve as it cut costs and avoided additional charges for legacy problems.

In the first three months of the year, Lloyds, which is partly owned by the British government, posted a profit of 1.16 billion pounds, or about $1.96 billion, compared with £1.54 billion in the prior year’s first quarter. The 2013 first-quarter results included a gain of £776 million from the sale of government securities.

The bank said it plans to go forward with an initial public offering of TSB Bank, which has 631 branches, in the summer and is on track to seek permission from the British government later this year to restart paying a dividend.

In the first quarter, Lloyds posted a statutory profit before tax of £1.37 billion, an important measure for the lender. It was the second quarter in a row that the bank had posted a statutory profit after last doing so in 2010.

António Horta-Osório, the Lloyds chief executive, called the results good progress from a more efficient and less risky operation focused on British consumers and businesses. The bank is benefiting from Britain’s economic recovery and supporting it, he said.

On an underlying basis, Lloyds posted a profit of £1.8 billion in the quarter, up 22 percent from the £1.48 billion it posted in the first quarter of last year. The underlying profit was inline with analysts’ expectations.

On a conference call with journalists on Thursday, George Culmer, the Lloyds finance director, said the bank continues to expect to seek permission from financial regulators in the second half of this year to restart its dividend, with the hope of paying a dividend for 2014.

The British government, which provided the Lloyds Banking Group with a £17 billion bailout during the financial crisis, holds 24.9 percent stake in the lender. Through two offerings, the government has reduced its stake from about 39 percent, and done so at a profit for the public.

Selling the government’s remaining holdings of Lloyds is a priority for George Osborne, the chancellor of the Exchequer.

No further provisions were taken by the bank in the first quarter to compensate customers who were wrongly sold loan insurance, a product that has cost British banks billions. The bank took a charge of £3.46 billion to cover so called payment protection insurance and other legacy issues in the fourth quarter. The bank has reserved £9.8 billion to cover potential claims on the insurance since 2011.

Net interest income - the measure of what a bank earns on its lending after deducting what it pays out on deposits and other liabilities - rose 10 percent to £2.81 billion, up from £2.55 billion a year ago.

The bank’s costs declined 5 percent to £2.29 billion in the quarter.

The bank’s core Tier 1 capital ratio, a measure of a bank’s ability to weather financial disturbances, rose to 10.7 percent, compared with 10.3 percent at the end of 2013.